[ 1 ] Dobes M，Shadbolt B.Khurana V G，et al.A multicenter study of primary brain tumor incidence in Australia（2000-2008）[J].Neuro Oncol，2011，13（7）：783-790. link1

[ 2 ] Deltour I，Johansen C，Auvinen A，et al.Time trends in brain tumor incidence rales in Denmark，Finland，Norway，and Sweden，1974-2003[J].JNatl Cancer Inst，2009，101（24）：1721-1724. link1

[ 3 ] Davis FG，Mecarthy BJ，Berger M S.Centralized databases available for describing primary brain tumor incidence，survival，and treatment:Central Brain Tumor Registry of the United States，Surveilance，Epidemiology and End Results，and National Cancer Data Base[J].Neuro Oncol，1999，1（3）：205-211. link1

[ 4 ] Pisarev MA，Dagrosa M A，Juvenal GJ.Boron neutron capture therapy in cancer:past，present and future[J].Arq Bras Endocrinol Metabol，2007，51（5）：852-856. link1

[ 5 ] LocherG L.Biological effects and therapeutic possibilities of neutrons[J].AmJRoentgenol，1936，36（1）：1-13.

[ 6 ] Dom R R.Boron neutron capture therapy（BNCT）：a radiation oncology perspective[J].Int J Radiat Oncol Biol Phys，1994，28（5）：1189-1201. link1

[ 7 ] 曹锐峰，章翔，吴景文.硼中子俘获疗法的硼携带剂研究进展[J].中华神经外科疾病研究杂志，2002，1（4）：376-378. link1

[ 8 ] Yang W，Barth R F，Wu G，et al.Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas[J].Appl Radiat Isot，2004，61（5）：981-985. link1

[ 9 ] Yang W，Wu G，Barth RF，et al.Molecular targeting and treatment of composite EGFR and EGFRvlll-positive gliomas usingboronated monoclonal antibodies[J].Clin Cancer Res，2008，14（3）：883-891. link1

[10] Hwang KC，Lai P D，Chiang CS，et al.Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells[J].Biomaterials，2010，31（32）：8419-8425. link1

[11] Thirumamagal BT，Zhao X B，Bandyopadhyaya AK，et al.Receplor-targeted lipesomal delivery of boron-containing cholesterol mimies for boron neutron capture therapy（BNCT）[J].Bioconjug Chem，2006，17（5）：1141-1150. link1

[12] Hiramatsu R，Kawabata S，Miyatake S，et al.Application of a novel boronated porphyrin（H（2）OCP）as a dual sensitizer for both PDT and BNCT[J].Lasers Surg Med，2011，43（l）：52-58. link1

[13] Gottumukkala V，Luguya R，Fronczek F R，et al.Synthesis and cellular studies of an octa-anionic 5，10，15，20-tetra[3，5-（nido-carboranylmethyl）phenyl]porphyrin（H（2）OCP）for ap-plication in BNCT[J].Bioorg Med Chem，2005，13（5）：1633-1640. link1

[14] Nakamura H，Ueda N，Ban HS，et al.Design and synthesis offluorescence-labeled closo-dodecaborate lipid:its liposome formation and in vivo imaging targeting of tumors for boron neutron capture therapy[J].Org Biomol Chem，2012，10（7）：1374一1380. link1

[15] Menichetti L，Petroni D，Panetta D，et al.A micro-PET/CT approach using O-（2-[18F]fluoroethyl）-L-tyrosine in an experimental animal model of F98 glioma for BNCT[J].Appl Radiat lsot，2011，69（12）：1717-1720. link1

[16] Liao A H，Chou F l，Kuo Y C，et al.Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT[J].Appl Radiat lsot，2010，68（3）：422一426. link1

[17] Menichetti L，Cionini L，Sauerwein W A，et al.Positron emis-sion tomography and[18F]BPA:a perspective application to assess tumour extraction of boron in BNCT[J].Appl Radiat lsot，2009，67（7/8 suppl）：S351-S354. link1

[18] Kawabata S，Miyatake S，Nonoguchi N，et al.Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients[J].Appl Radiat Isot，2009，67（7/8 suppl）：S15-$18. link1

[19] Miyatake S，Kawabata S，Yokoyama K，et al.Survival benefit of boron neutron capture therapy for recurrent malignant gliomas[J].Appl Radiat Isot，2009，67（7/8 suppl）：S22-S24. link1

[20] Charles N，Holland E C.Brain tumor treatment increases the number of cancer stem-like cells[J].Expert Rev Neurother，2009，9（10）：1447-1449. link1

[21] Heywood RM，Marcus H J，Ryan DJ，et al.A review of the role of stem cells in the development and treatment of glioma[J].Acta Neurochir（Wien），2012，154（6）：951-969. link1

[22] Colao A，Grasso L F，Pivonello R，et al.Therapy of aggressive pituitary tumors[J].Expert Opin Pharmacother，2011，12（10）：1561-1570. link1

[23] Aghi MK.Management of recurent and refractory Cushing disease[J].Nat Clin Pract Endocrinol Metab，2008，4（10）：560-568. link1

[24] 马四海，姚勇，代从新，等.替莫唑胺治疗难治性垂体腺瘤一例报告并文献复习[J].中华神经外科杂志，2011，27（5）：584-588.

[25] Liu X，MaS，Yao Y，et al.Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior[J].Neurosurgery，2012，70（5）：1274-1280. link1

[26] Sudimack JJ，Adams D，Rotaru J，et al.Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy[J].Pharm Res，2002，19（10）：1502-1508. link1

[27] Thirumamagal B T，Zhao XB，Bandyopadhyaya A K，et al.Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy（BNCT）[J].Bioconjug Chem，2006，17（5）：1141-1150. link1